GlassScriptPhysician profile
Nimisha Jacob
NPI 1780458331
$968.54
in general payments reported to CMS, 2019-2025
13 companies · $796 in 2025
The $796 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $173 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $210.49 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $134.51 | 2024-2025 | |
| Lilly USA, LLC | $109.45 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $87.88 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $76.11 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.01 | 2025 | Jardiance |
| Astellas Pharma US INC | $72.00 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $51.99 | 2025 | Airsupra, Farxiga |
| Pfizer INC. | $36.22 | 2025 | |
| Avvisto Therapeutics, LLC | $34.16 | 2025 | Cycloset |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.16 | 2024-2025 | Xifaxan |
| Amgen INC. | $28.90 | 2024-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $21.66 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimisha Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.